Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.
about
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitorsEpithelial junction opener JO-1 improves monoclonal antibody therapy of cancerPreclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).A comparison of epithelial-to-mesenchymal transition and re-epithelializationEpithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor ModelsCombined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancerMetalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancerEMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceStrategies to increase drug penetration in solid tumors.Intestinal stem cells and the colorectal cancer microenvironment.Gene expression profiling for targeted cancer treatment.Overcoming physical barriers in cancer therapy.Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs.A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
P2860
Q35212644-6D660D9B-4857-48E5-86DD-1D1C09B35C57Q35552521-B912B375-9187-4984-A57F-F3B4422D8CC1Q35651085-32A87CAD-6376-4E38-A0E1-BD0CCE1A3A9BQ36618624-3A5935E5-F7D6-4940-B935-46F649C4A777Q36678367-0F0CD121-FA40-4451-860B-7D1BD9007FC7Q36825407-A1DF3292-2682-48EC-B3D6-8CBBEB49C10CQ37146300-3F60C030-2B36-407F-824C-BAD0F1D84860Q37620891-667E3061-E941-4E66-B773-EC216205D523Q38040369-0B77D847-F685-45B9-9413-2797C746E6B5Q38118934-CF1EC7C4-7F2E-47EF-88E8-68C6315101F5Q38125197-0A8A2B8D-9008-479B-9F08-530461C00643Q38192621-6835CAC4-FE60-4D4A-8928-F346FC7F93ABQ38259249-91577EA8-2D49-4D8D-BC1A-10F932497207Q38318962-3165AE62-2E05-4A00-9D10-ECDD2370FE4BQ38962519-FDB2BC3D-7204-4F85-975D-ABD566C8914FQ39358604-75BA2ACE-275A-4CFB-843A-87F4710DF4E1Q41159551-1F866B1F-C9D5-4540-8AF6-ED1497489770Q41978535-300C2A77-A485-416F-9F5A-3B5F7C77D3E8
P2860
Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Stem cell property epithelial- ...... in KRAS wild-type tumor cells.
@en
Stem cell property epithelial- ...... twork for predicting cetuximab
@nl
type
label
Stem cell property epithelial- ...... in KRAS wild-type tumor cells.
@en
Stem cell property epithelial- ...... twork for predicting cetuximab
@nl
prefLabel
Stem cell property epithelial- ...... in KRAS wild-type tumor cells.
@en
Stem cell property epithelial- ...... twork for predicting cetuximab
@nl
P2093
P2860
P50
P356
P1476
Stem cell property epithelial- ...... in KRAS wild-type tumor cells.
@en
P2093
Alejandro Vazquez-Martin
Bernardo Queralt
Cristina Oliveras-Ferraros
Luciana Báez
Raquel Guardeño
Sílvia Cufí
P2860
P356
10.1002/JCB.22952
P577
2011-01-01T00:00:00Z